AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical company's shares ...
AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a ...
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...
Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback